Thursday, 4 January 2018

Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with ...

  1. Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with ...  GlobeNewswire (press release)Full coverage
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)